FI933328A0 - Antigen producerande protein - Google Patents

Antigen producerande protein

Info

Publication number
FI933328A0
FI933328A0 FI933328A FI933328A FI933328A0 FI 933328 A0 FI933328 A0 FI 933328A0 FI 933328 A FI933328 A FI 933328A FI 933328 A FI933328 A FI 933328A FI 933328 A0 FI933328 A0 FI 933328A0
Authority
FI
Finland
Prior art keywords
pct
protein
sec
amino acid
acid sequence
Prior art date
Application number
FI933328A
Other languages
English (en)
Other versions
FI933328A (fi
FI110615B (fi
Inventor
Robert Allan Mastico
Peter George Stockley
Simon John Talbot
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of FI933328A0 publication Critical patent/FI933328A0/fi
Publication of FI933328A publication Critical patent/FI933328A/fi
Application granted granted Critical
Publication of FI110615B publication Critical patent/FI110615B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/826Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Soil Working Implements (AREA)
FI933328A 1991-01-24 1993-07-23 Menetelmä modifioidun kapsidin muodostavan proteiinin valmistamiseksi FI110615B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9101550 1991-01-24
GB919101550A GB9101550D0 (en) 1991-01-24 1991-01-24 Antigen-presenting chimaeric protein
PCT/GB1992/000124 WO1992013081A1 (en) 1991-01-24 1992-01-22 Antigen-presenting capsid with fusion ms2-coat protein
GB9200124 1992-01-22

Publications (3)

Publication Number Publication Date
FI933328A0 true FI933328A0 (fi) 1993-07-23
FI933328A FI933328A (fi) 1993-09-07
FI110615B FI110615B (fi) 2003-02-28

Family

ID=10688936

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933328A FI110615B (fi) 1991-01-24 1993-07-23 Menetelmä modifioidun kapsidin muodostavan proteiinin valmistamiseksi

Country Status (15)

Country Link
US (1) US5534257A (fi)
EP (1) EP0572433B1 (fi)
JP (1) JP3187832B2 (fi)
KR (1) KR100197819B1 (fi)
AT (1) ATE201449T1 (fi)
AU (1) AU653387B2 (fi)
CA (1) CA2101070C (fi)
DE (1) DE69231837T8 (fi)
FI (1) FI110615B (fi)
GB (2) GB9101550D0 (fi)
IE (1) IE920200A1 (fi)
NO (1) NO313917B1 (fi)
NZ (1) NZ241373A (fi)
WO (1) WO1992013081A1 (fi)
ZA (1) ZA92511B (fi)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1995005454A1 (en) * 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
HUP9901109A3 (en) 1996-03-01 1999-11-29 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
US5766905A (en) * 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
SI1497438T1 (sl) 2002-04-25 2010-03-31 Crucell Holland Bv Sredstva in postopki za pripravo adenovirusnih vektorjev
CA2487849A1 (en) * 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
DK1524994T3 (da) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
KR20050115913A (ko) 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Melan―a 펩티드 유사체-바이러스-양-입자컨쥬게이트
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
AU2005291231B2 (en) * 2004-10-05 2010-12-23 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
ATE515566T1 (de) * 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
EP1746165A1 (en) * 2005-07-21 2007-01-24 Cytos Biotechnology AG Scalable fermentation process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc HETERO DUPLEX TRACKING TEST
ES2427994T3 (es) 2006-06-12 2013-11-05 Cytos Biotechnology Ag Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
RU2568872C1 (ru) * 2014-10-15 2015-11-20 Игорь Геннадьевич Сивов Лекарственное средство для лечения вирусного гепатита с
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637049B2 (en) * 1988-05-05 1993-05-20 American Cyanamid Company Recombinant flagellin vaccines
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
IL91462A0 (en) * 1988-08-30 1990-04-29 Applied Research Systems Recombinant fusion proteins and dna encoding for such a protein
JPH04500308A (ja) * 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌

Also Published As

Publication number Publication date
WO1992013081A1 (en) 1992-08-06
ATE201449T1 (de) 2001-06-15
NO932644D0 (no) 1993-07-22
AU653387B2 (en) 1994-09-29
EP0572433A1 (en) 1993-12-08
GB9201372D0 (en) 1992-03-11
NZ241373A (en) 1993-04-28
FI933328A (fi) 1993-09-07
US5534257A (en) 1996-07-09
CA2101070C (en) 2003-04-01
JPH06504907A (ja) 1994-06-09
AU1173792A (en) 1992-08-27
FI110615B (fi) 2003-02-28
DE69231837D1 (de) 2001-06-28
GB2253626A (en) 1992-09-16
JP3187832B2 (ja) 2001-07-16
CA2101070A1 (en) 1992-07-25
GB2253626B (en) 1995-02-08
NO313917B1 (no) 2002-12-23
GB9101550D0 (en) 1991-03-06
DE69231837T8 (de) 2004-08-12
IE920200A1 (en) 1992-07-29
KR100197819B1 (ko) 1999-06-15
ZA92511B (en) 1992-11-25
NO932644L (no) 1993-09-23
KR930703449A (ko) 1993-11-30
DE69231837T2 (de) 2001-10-18
EP0572433B1 (en) 2001-05-23

Similar Documents

Publication Publication Date Title
FI933328A0 (fi) Antigen producerande protein
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
FI102389B1 (fi) Menetelmä herneproteiinihydrolysaatin valmistamiseksi
BR9809656A (pt) Composição imunopotencializante
NO943739D0 (no) Vaksiner inneholdende ikke-ioniske overflate-aktive vaksiner
IL122431A0 (en) Combined vaccine comprising a polysaccharide antigen conjugated to a carrier protein
CO5280094A1 (es) Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo
MA24638A1 (fr) Vaccin
ATE112239T1 (de) Vaterit und verfahren zu dessen herstellung.
ATE398137T1 (de) Porphyromonas gingivalis antigene zur diagnose und behandlung von periodontitis
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
GB9108056D0 (en) Synthetic antigen
DE69923996D1 (de) Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
KR950701821A (ko) 피임 백신(contraceptive vaccine)
ITRM920157A1 (it) Procedimento per la preparazione di vaccini basato sulla identificazione di sequenze amminoacidiche dell'antigene simili a sequenze amminoacidiche dell'organismo da immunizzare, e vaccini cosi' ottenibili.